Integra LifeSciences (NASDAQ:IART) Updates FY 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided EPS guidance of 2.410-2.490 for the period, compared to the consensus EPS estimate of 2.450. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Integra LifeSciences also updated its Q4 guidance to $0.81-0.89 EPS.

Wall Street Analysts Forecast Growth

IART has been the topic of several recent analyst reports. JMP Securities dropped their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Citigroup cut their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, October 1st. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Morgan Stanley boosted their target price on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $26.50.

Integra LifeSciences Trading Up 1.7 %

NASDAQ:IART opened at $24.53 on Tuesday. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The stock’s 50 day simple moving average is $18.62 and its 200-day simple moving average is $24.46. The firm has a market cap of $1.90 billion, a P/E ratio of 83.17, a PEG ratio of 0.66 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 EPS. Equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.